M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
JAMA oncology review validates Exact Sciences Corp's Oncotype DX test accuracy across racial and ethnic groups
Cancer screening and diagnostic tests provider Exact Sciences Corp (Nasdaq: EXAS) announced on Monday that newly published review in JAMA Oncology confirms the reliability of the company's Oncotype DX Breast Recurrence Score test in predicting breast cancer outcomes and chemotherapy benefit...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search